John Mohr
Chief Tech/Sci/R&D Officer chez SCPHARMACEUTICALS INC.
Profil
John Mohr is currently the Senior VP-Clinical Development & Medical Affairs at scPharmaceuticals, Inc. He previously worked as Vice President-Medical Affairs at The Medicines Co. and Tetraphase Pharmaceuticals, Inc. He also worked as an Assistant Professor at The University of Texas Medical School At Houston.
Dr. Mohr received his undergraduate degree from Texas A&M University and his doctorate from the University of Houston.
Postes actifs de John Mohr
| Sociétés | Poste | Début |
|---|---|---|
| SCPHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Anciens postes connus de John Mohr
| Sociétés | Poste | Fin |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2016 |
| THE MEDICINES COMPANY | Chief Tech/Sci/R&D Officer | 01/06/2015 |
| The University of Texas Medical School At Houston | Corporate Officer/Principal | 01/10/2007 |
Formation de John Mohr
| Texas A&M University | Undergraduate Degree |
| University of Houston | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCPHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
